Literature DB >> 15629318

Photodynamic therapy for retinal angiomatous proliferations and pigment epithelium detachment.

Francesco Boscia1, Claudio Furino, Luigi Sborgia, Michele Reibaldi, Carlo Sborgia.   

Abstract

PURPOSE: To evaluate results of photodynamic therapy (PDT) with verteporfin for subfoveal neovascular age-related macular degeneration (ARMD) with retinal angiomatous proliferation (RAP) and pigment epithelial detachment (PED).
DESIGN: Interventional case series.
METHODS: Thirteen eyes (11 stage 2 and 2 stage 3 RAP) underwent PDT. Best-corrected visual acuity (BCVA), fluorescein and indocyanine-green angiography were performed to evaluate the outcome.
RESULTS: After 13.5 +/- 2.5 months and 1.7 +/- 0.4 treatments, mean BCVA decreased from 20/73 to 20/174 (P = .04). Occlusion of RAP and flattening of PED was observed in three eyes, and persistence of PED in six. Two eyes deteriorated to disciform lesions, one developed hemorrhagic PED, and one evolved toward stage 3 RAP. Three eyes, with PED exceeding 50% of the entire lesion, developed retinal pigment epithelium tear.
CONCLUSIONS: PDT might prove effective for neovascular ARMD with RAP and small PED, whereas it might cause acute retinal pigment epithelium tear for RAP with PED exceeding 50% of the lesion.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15629318     DOI: 10.1016/j.ajo.2004.06.072

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  29 in total

Review 1.  [Pigment epithelial detachment in exudative macular degeneration: clinical characteristics and therapeutic options].

Authors:  A Lommatzsch
Journal:  Ophthalmologe       Date:  2010-12       Impact factor: 1.059

2.  Retinal angiomatous proliferation: combined therapy of intravitreal triamcinolone acetonide and PDT versus PDT alone.

Authors:  Ilse Krebs; Katharina Krepler; Ulrike Stolba; Alexandra Goll; Susanne Binder
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-08-03       Impact factor: 3.117

3.  Prognosis of untreated occult choroidal neovascularization.

Authors:  Ilse Krebs; Ulrike Stolba; Carl Glittenberg; Orang Seyeddain; Thomas Benesch; Susanne Binder
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-10-27       Impact factor: 3.117

4.  Photodynamic therapy with verteporfin for retinal angiomatous proliferation.

Authors:  Francesco Boscia; Maurizio Battaglia Parodi; Claudio Furino; Michele Reibaldi; Carlo Sborgia
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-03-09       Impact factor: 3.117

5.  [Therapy of stage III retinal angiomatous proliferation. Intravitreal ranibizumab injections].

Authors:  M Maier; C Perz; J Bockmaier; N Feucht; C P Lohmann
Journal:  Ophthalmologe       Date:  2013-12       Impact factor: 1.059

6.  [Selective retina therapy in central serous chorioretinopathy with detachment of the pigmentary epithelium].

Authors:  C Klatt; H Elsner; E Pörksen; R Brinkmann; A Bunse; R Birngruber; J Roider
Journal:  Ophthalmologe       Date:  2006-10       Impact factor: 1.059

7.  [Intravitreal ranibizumab for the treatment of retinal angiomatous proliferation].

Authors:  J Maaß; D Sandner; E Matthé
Journal:  Ophthalmologe       Date:  2017-06       Impact factor: 1.059

8.  Two-year results of combined intravitreal ranibizumab and photodynamic therapy for retinal angiomatous proliferation.

Authors:  Masaaki Saito; Tomohiro Iida; Mariko Kano; Kanako Itagaki
Journal:  Jpn J Ophthalmol       Date:  2016-01       Impact factor: 2.447

9.  Enlargement of the hypofluorescent post photodynamic therapy treatment spot after a combination of photodynamic therapy with an intravitreal injection of bevacizumab for retinal angiomatous proliferation.

Authors:  Alexandros A Rouvas; Thanos D Papakostas; Ioannis D Ladas; Ioannis Vergados
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-10-24       Impact factor: 3.117

10.  Two-year results of combined intravitreal anti-VEGF agents and photodynamic therapy for retinal angiomatous proliferation.

Authors:  Masaaki Saito; Tomohiro Iida; Mariko Kano
Journal:  Jpn J Ophthalmol       Date:  2012-12-04       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.